Regado Biosciences, Inc. Kicks Off Big Clinical Trial for Heart Drug

Regado Biosciences (NASDAQ: RGDO) will now have the chance to prove that the two-pronged anticoagulant it pitched at its IPO roadshow is all it’s cracked up to be. The Basking Ridge, NJ-based biotech has officially enrolled the first patient in a massive late-stage clinical trial for its lead drug, REG-1. Regado expects to enroll a total of 13,200 patients at 500 sites around the world and complete the trial in 2015.

Help employers find you! Check out all the jobs and post your resume.